RegulatoryScience Community

Back to discussions
Expand all | Collapse all

1Oct26 noon to 1pm ET Discussion: FDA Draft Guidance Container Closure Systems for Human Drugs and Biological Products

  • 1.  1Oct26 noon to 1pm ET Discussion: FDA Draft Guidance Container Closure Systems for Human Drugs and Biological Products

    Community Leadership
    Posted 13 days ago
    Date: October 1, 2026
    Duration: 60 minutes
    Format: Teams Meeting
    Meeting Description
    FDA's draft guidance, Container Closure Systems for Human Drugs and Biological Products, represents the first comprehensive update to the agency's overarching CCS recommendations in nearly 30 years and is currently open for public comment through October 13, 2026. The guidance introduces a risk-based framework for evaluating the quality, suitability, and control of container closure systems across drugs, biologics, combination products, and certain OTC products. 
    Join colleagues from Pharmaceutical Quality and Regulatory Science for an open scientific discussion to identify key scientific, regulatory, and implementation issues that may warrant comment.
    This is intended as a collaborative scientific exchange and does not represent a consensus position of any organization.
    Objectives
    • Review the scope and major provisions of the draft guidance.
    • Identify areas requiring clarification, additional examples, or future guidance.
    • Explore impacts on biologics, combination products, generics, and OTC products.
    • Capture potential comments and recommendations ahead of the FDA deadline.
    Background Materials
    The Federal Register notice is here: https://www.federalregister.gov/documents/2026/08/14/2026-16638/container-closure-systems-for-human-drugs-and-biological-products-draft-guidance-for-industry. Click or tap if you trust this link." rel="noopener noreferrer" data-auth="NotApplicable" data-linkindex="73"> Container Closure Systems for Human Drugs and Biological Products (91 FR 52700, 14 August 2026; Docket No. FDA-2026-D-7957). The draft guidance itself is at https://www.fda.gov/media/194220/download. Click or tap if you trust this link." rel="noopener noreferrer" data-auth="NotApplicable" data-linkindex="74"> https://www.fda.gov/media/194220/download.
    ________________________________________________________________________________
    Microsoft Teams meeting
    Meeting ID: 228 271 334 889 496
    Passcode: rB7Nz3Y3
    Dial in by phone
    +1 240-752-9082,,21405207# United States, Bethesda
    (833) 851-0265,,21405207# United States (Toll-free)
    Phone conference ID: 214 052 07#
    Join on a video conferencing device
    Tenant key: [email protected]
    Video ID: 112 531 805 6
    For organizers: 19_meeting_ZjAxYTcwNjgtYmZiZi00NGRiLWE4ZWEtMzA2NDg3OGVkZTgy@thread.v2&messageId=0&language=en-US" target="_blank" class="x_me-email-link OWAAutoLink" rel="noreferrer noopener" data-auth="NotApplicable">Meeting options | Reset dial-in PIN


    ------------------------------
    Allison Radwick Ph.D.
    Sr Regulatory & Policy Comms Mgr
    USP
    Coatesville PA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------